Urine tenofovir testing for real‐time PrEP adherence feedback: a qualitative study involving transgender women in Uganda
Journal of the International AIDS Society · 2024
DOI: 10.1002/jia2.26255 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the International AIDS Society, 2024. Verfasst von Andrew Mujugira und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Infectious Diseases Institute Limited, Makerere University, Kampala, Uganda. Hauptthemen laut MEDLINE: Tenofovir, Pre-Exposure Prophylaxis, HIV Infections, Transgender Persons. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Introduction
Adherence counselling with point‐of‐care (POC) drug‐level feedback using a novel tenofovir assay may support pre‐exposure prophylaxis (PrEP) adherence; however, perceptions of urine testing and its impact on adherence are not well studied. We qualitatively examined how POC tenofovir testing was experienced by transgender women (TGW) in Uganda.
Methods
Within a cluster randomized trial of peer‐delivered HIV self‐testing, self‐sampling for sexually transmitted infections and PrEP among HIV‐negative TGW showing overall low PrEP prevention‐effective adherence (NCT04328025), we conducted a nested qualitative sub‐study of the urine POC assay among a random sample of 30 TGW (August 2021−February 2022). TGW interviews explored: (1) experiences with POC urine tenofovir testing and (2) perceptions of PrEP adherence counselling with drug‐level feedback. We used an inductive content analytic approach for analysis.
Results
Median age was 21 years (interquartile range 20–24), and 70% engaged in sex work. Four content categories describe how TGW experienced POC urine tenofovir testing: (1) Urine tenofovir testing was initially met with scepticism: Testing urine to detect PrEP initially induced anxiety, with some perceptions of being intrusive and unwarranted. With counselling, however, participants found POC testing acceptable and beneficial. (2) Alignment of urine test results and adherence behaviours: Drug‐level feedback aligned with what TGW knew about their adherence. Concurrence between pill taking and tenofovir detection in urine reinforced confidence in test accuracy. (3) Interpretation of urine tenofovir results: TGW familiar with the interpretation of oral‐fluid HIV self‐tests knew that two lines on the test device signified positivity (presence of HIV). However, two lines on the urine test strip indicated a positive result for non‐adherence (absence of tenofovir), causing confusion. Research nurses explained the difference in test interpretation to participants’ satisfaction. (4) White coat dosing: Some TGW deliberately chose not to attend scheduled clinic appointments to avoid detecting their PrEP non‐adherence during urine testing. They restarted PrEP before returning to clinic, a behaviour called “white coat dosing.” Conclusions Incorporating POC urine testing into routine PrEP adherence counselling was acceptable and potentially beneficial for TGW but required attention to context. Additional research is needed to identify effective strategies for optimizing adherence monitoring and counselling for this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Infectious Diseases Institute Limited, Makerere University, Kampala, Uganda.
- Department of Global Health, University of Washington, Seattle, Washington, USA.
- Transgender Equality Uganda, Kampala, Uganda.
- Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- Harvard Global, Cambridge, Massachusetts, USA.
- Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Andrew Mujugira, Norma C Ware, Monica Gandhi, Jessica E Haberer
Förderung
- NIMH NIH HHS
- NIAID NIH HHS
Zitieren
APA
Mujugira, A., Karungi, B., Mugisha, J., Nakyanzi, A., Nampewo, O., Naddunga, F., Kamusiime, B., Nsubuga, R., Nyanzi, K. R., Muwonge, T. R., Wyatt, M. A., Ware, N. C., Gandhi, M., & Haberer, J. E. (2024). Urine tenofovir testing for real‐time PrEP adherence feedback: a qualitative study involving transgender women in Uganda. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26255
Vancouver
Mujugira A, Karungi B, Mugisha J, Nakyanzi A, Nampewo O, Naddunga F, et al. Urine tenofovir testing for real‐time PrEP adherence feedback: a qualitative study involving transgender women in Uganda. Journal of the International AIDS Society. 2024. doi:10.1002/jia2.26255
BibTeX
@article{Mujugira2024,
author = {Mujugira, Andrew and Karungi, Beyonce and Mugisha, Jackson and Nakyanzi, Agnes and Nampewo, Olivia and Naddunga, Faith and Kamusiime, Brenda and Nsubuga, Rogers and Nyanzi, Kikulwe R and Muwonge, Timothy R and Wyatt, Monique A and Ware, Norma C and Gandhi, Monica and Haberer, Jessica E},
title = {Urine tenofovir testing for real‐time PrEP adherence feedback: a qualitative study involving transgender women in Uganda},
journal = {Journal of the International AIDS Society},
year = {2024},
doi = {10.1002/jia2.26255}
}
EUVIMED